Background: Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG. Methods: We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model. Results: A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95% confidence interval 1.09–1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12–1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01–1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1–1.68); p = 0.005]. The limitations of a retrospective study are applicable. Conclusion: Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted.

Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor

Ferro M.;Di Lorenzo G.;Bove P.;Cimmino A.;
2020

Abstract

Background: Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG. Methods: We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model. Results: A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95% confidence interval 1.09–1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12–1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01–1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1–1.68); p = 0.005]. The limitations of a retrospective study are applicable. Conclusion: Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted.
Campo DC Valore Lingua
dc.authority.ancejournal WORLD JOURNAL OF UROLOGY en
dc.authority.orgunit Istituto di genetica e biofisica "Adriano Buzzati Traverso"- IGB - Sede Napoli en
dc.authority.people Ferro M. en
dc.authority.people Di Lorenzo G. en
dc.authority.people Vartolomei M. D. en
dc.authority.people Bruzzese D. en
dc.authority.people Cantiello F. en
dc.authority.people Lucarelli G. en
dc.authority.people Musi G. en
dc.authority.people Di Stasi S. en
dc.authority.people Hurle R. en
dc.authority.people Guazzoni G. en
dc.authority.people Busetto G. M. en
dc.authority.people Gabriele A. en
dc.authority.people Del Giudice F. en
dc.authority.people Damiano R. en
dc.authority.people Perri F. en
dc.authority.people Perdona S. en
dc.authority.people Verze P. en
dc.authority.people Borghesi M. en
dc.authority.people Schiavina R. en
dc.authority.people Almeida G. L. en
dc.authority.people Bove P. en
dc.authority.people Lima E. en
dc.authority.people Autorino R. en
dc.authority.people Crisan N. en
dc.authority.people Farhan A. R. A. en
dc.authority.people Battaglia M. en
dc.authority.people Russo G. I. en
dc.authority.people Ieluzzi V. en
dc.authority.people Morgia G. en
dc.authority.people De Placido P. en
dc.authority.people Terracciano D. en
dc.authority.people Cimmino A. en
dc.authority.people Scafuri L. en
dc.authority.people Mirone V. en
dc.authority.people De Cobelli O. en
dc.authority.people Shariat S. en
dc.authority.people Sonpavde G. en
dc.authority.people Buonerba C. en
dc.collection.id.s b3f88f24-048a-4e43-8ab1-6697b90e068e *
dc.collection.name 01.01 Articolo in rivista *
dc.contributor.appartenenza ASR - Ufficio Supporto alla Ricerca e Grant *
dc.contributor.appartenenza Istituto di Geoscienze e Georisorse - IGG - Sede Pisa *
dc.contributor.appartenenza Istituto di genetica e biofisica "Adriano Buzzati Traverso"- IGB - Sede Napoli *
dc.contributor.appartenenza Istituto di linguistica computazionale "Antonio Zampolli" - ILC *
dc.contributor.appartenenza.mi 895 *
dc.contributor.appartenenza.mi 907 *
dc.contributor.appartenenza.mi 918 *
dc.contributor.appartenenza.mi 1166 *
dc.contributor.area Non assegn *
dc.contributor.area Non assegn *
dc.contributor.area Non assegn *
dc.contributor.area Non assegn *
dc.date.accessioned 2024/12/13 17:55:18 -
dc.date.available 2024/12/13 17:55:18 -
dc.date.firstsubmission 2024/12/13 17:53:24 *
dc.date.issued 2020 -
dc.date.submission 2024/12/13 17:53:24 *
dc.description.abstracteng Background: Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG. Methods: We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model. Results: A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95% confidence interval 1.09–1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12–1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01–1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1–1.68); p = 0.005]. The limitations of a retrospective study are applicable. Conclusion: Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted. -
dc.description.allpeople Ferro, M.; Di Lorenzo, G.; Vartolomei, M. D.; Bruzzese, D.; Cantiello, F.; Lucarelli, G.; Musi, G.; Di Stasi, S.; Hurle, R.; Guazzoni, G.; Busetto, G. M.; Gabriele, A.; Del Giudice, F.; Damiano, R.; Perri, F.; Perdona, S.; Verze, P.; Borghesi, M.; Schiavina, R.; Almeida, G. L.; Bove, P.; Lima, E.; Autorino, R.; Crisan, N.; Farhan, A. R. A.; Battaglia, M.; Russo, G. I.; Ieluzzi, V.; Morgia, G.; De Placido, P.; Terracciano, D.; Cimmino, A.; Scafuri, L.; Mirone, V.; De Cobelli, O.; Shariat, S.; Sonpavde, G.; Buonerba, C. -
dc.description.allpeopleoriginal Ferro M.; Di Lorenzo G.; Vartolomei M.D.; Bruzzese D.; Cantiello F.; Lucarelli G.; Musi G.; Di Stasi S.; Hurle R.; Guazzoni G.; Busetto G.M.; Gabriele A.; Del Giudice F.; Damiano R.; Perri F.; Perdona S.; Verze P.; Borghesi M.; Schiavina R.; Almeida G.L.; Bove P.; Lima E.; Autorino R.; Crisan N.; Farhan A.R.A.; Battaglia M.; Russo G.I.; Ieluzzi V.; Morgia G.; De Placido P.; Terracciano D.; Cimmino A.; Scafuri L.; Mirone V.; De Cobelli O.; Shariat S.; Sonpavde G.; Buonerba C. en
dc.description.fulltext restricted en
dc.description.numberofauthors 38 -
dc.identifier.doi 10.1007/s00345-019-02754-2 en
dc.identifier.isi WOS:000511866800018 en
dc.identifier.scopus 2-s2.0-85064646644 en
dc.identifier.source scopus *
dc.identifier.uri https://hdl.handle.net/20.500.14243/518413 -
dc.identifier.url https://link.springer.com/article/10.1007/s00345-019-02754-2 en
dc.language.iso eng en
dc.relation.firstpage 143 en
dc.relation.issue 1 en
dc.relation.lastpage 150 en
dc.relation.numberofpages 8 en
dc.relation.volume 38 en
dc.subject.keywordseng Basophils -
dc.subject.keywordseng BCG -
dc.subject.keywordseng Bladder cancer -
dc.subject.singlekeyword Basophils *
dc.subject.singlekeyword BCG *
dc.subject.singlekeyword Bladder cancer *
dc.title Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor en
dc.type.circulation Internazionale en
dc.type.driver info:eu-repo/semantics/article -
dc.type.full 01 Contributo su Rivista::01.01 Articolo in rivista it
dc.type.miur 262 -
iris.isi.extIssued 2020 -
iris.isi.extTitle Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guerin after transurethral resection of the bladder tumor -
iris.isi.metadataErrorDescription 0 -
iris.isi.metadataErrorType ERROR_NO_MATCH -
iris.isi.metadataStatus ERROR -
iris.mediafilter.data 2025/04/09 04:11:34 *
iris.orcid.lastModifiedDate 2025/02/17 14:11:30 *
iris.orcid.lastModifiedMillisecond 1739797890113 *
iris.scopus.extIssued 2020 -
iris.scopus.extTitle Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor -
iris.sitodocente.maxattempts 1 -
iris.unpaywall.bestoahost repository *
iris.unpaywall.bestoaversion publishedVersion *
iris.unpaywall.doi 10.1007/s00345-019-02754-2 *
iris.unpaywall.hosttype repository *
iris.unpaywall.isoa true *
iris.unpaywall.journalisindoaj false *
iris.unpaywall.landingpage http://hdl.handle.net/11573/1261872 *
iris.unpaywall.license other-oa *
iris.unpaywall.metadataCallLastModified 20/02/2025 23:23:47 -
iris.unpaywall.metadataCallLastModifiedMillisecond 1740090227853 -
iris.unpaywall.oastatus green *
iris.unpaywall.pdfurl https://iris.uniroma1.it/bitstream/11573/1261872/1/Busetto_Basophil-bladder-cancer_2019.pdf *
scopus.authority.ancejournal WORLD JOURNAL OF UROLOGY###0724-4983 *
scopus.category 2748 *
scopus.contributor.affiliation European Institute of Oncology -
scopus.contributor.affiliation Università degli Studi del Molise -
scopus.contributor.affiliation University of Medicine and Pharmacy -
scopus.contributor.affiliation Federico II University of Naples -
scopus.contributor.affiliation Magna Graecia University of Catanzaro -
scopus.contributor.affiliation University of Bari -
scopus.contributor.affiliation European Institute of Oncology -
scopus.contributor.affiliation Tor Vegata University -
scopus.contributor.affiliation Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital -
scopus.contributor.affiliation Humanitas University -
scopus.contributor.affiliation Sapienza University of Rome -
scopus.contributor.affiliation Sapienza University of Rome -
scopus.contributor.affiliation Sapienza University of Rome -
scopus.contributor.affiliation Magna Graecia University of Catanzaro -
scopus.contributor.affiliation Fondazione “G. Pascale” IRCCS -
scopus.contributor.affiliation Fondazione “G. Pascale” IRCCS -
scopus.contributor.affiliation University of Naples “Federico II” -
scopus.contributor.affiliation University of Bologna -
scopus.contributor.affiliation University of Bologna -
scopus.contributor.affiliation University of Vale do Itajaí -
scopus.contributor.affiliation Tor Vergata University of Rome -
scopus.contributor.affiliation University of Minho -
scopus.contributor.affiliation Virginia Commonwealth University -
scopus.contributor.affiliation University of Medicine and Pharmacy “Iuliu Haţeganu,” -
scopus.contributor.affiliation Magna Graecia University of Catanzaro -
scopus.contributor.affiliation University of Bari -
scopus.contributor.affiliation University of Catania -
scopus.contributor.affiliation Federico II University of Naples -
scopus.contributor.affiliation University of Catania -
scopus.contributor.affiliation Federico II University of Naples -
scopus.contributor.affiliation University of Naples “Federico II” -
scopus.contributor.affiliation CNR -
scopus.contributor.affiliation Federico II University of Naples -
scopus.contributor.affiliation University of Naples “Federico II” -
scopus.contributor.affiliation European Institute of Oncology -
scopus.contributor.affiliation Medical University of Vienna -
scopus.contributor.affiliation Harvard Medical School -
scopus.contributor.affiliation Zoo-prophylactic Institute of Southern Italy -
scopus.contributor.afid 60030442 -
scopus.contributor.afid 60014096 -
scopus.contributor.afid 60003322 -
scopus.contributor.afid 60017293 -
scopus.contributor.afid 60069616 -
scopus.contributor.afid 60022778 -
scopus.contributor.afid 60030442 -
scopus.contributor.afid 60027509 -
scopus.contributor.afid 60024876 -
scopus.contributor.afid 60107210 -
scopus.contributor.afid 60032350 -
scopus.contributor.afid 60032350 -
scopus.contributor.afid 60032350 -
scopus.contributor.afid 60069616 -
scopus.contributor.afid 60017517 -
scopus.contributor.afid 60017517 -
scopus.contributor.afid 60017293 -
scopus.contributor.afid 60028218 -
scopus.contributor.afid 60028218 -
scopus.contributor.afid 60016828 -
scopus.contributor.afid 60027509 -
scopus.contributor.afid 60094395 -
scopus.contributor.afid 60002476 -
scopus.contributor.afid 60013180 -
scopus.contributor.afid 60069616 -
scopus.contributor.afid 60022778 -
scopus.contributor.afid 60010146 -
scopus.contributor.afid 60017293 -
scopus.contributor.afid 60010146 -
scopus.contributor.afid 60017293 -
scopus.contributor.afid 60017293 -
scopus.contributor.afid 60025668 -
scopus.contributor.afid 60017293 -
scopus.contributor.afid 60017293 -
scopus.contributor.afid 60030442 -
scopus.contributor.afid 60011394 -
scopus.contributor.afid 60002746 -
scopus.contributor.afid 121863367 -
scopus.contributor.auid 22834576900 -
scopus.contributor.auid 57581564600 -
scopus.contributor.auid 56441729500 -
scopus.contributor.auid 6602597648 -
scopus.contributor.auid 6507196350 -
scopus.contributor.auid 8595781600 -
scopus.contributor.auid 23110857300 -
scopus.contributor.auid 7004613074 -
scopus.contributor.auid 57192340986 -
scopus.contributor.auid 7006960676 -
scopus.contributor.auid 37049750600 -
scopus.contributor.auid 57208392935 -
scopus.contributor.auid 56637122900 -
scopus.contributor.auid 7103083852 -
scopus.contributor.auid 57477364900 -
scopus.contributor.auid 6603269860 -
scopus.contributor.auid 12767754400 -
scopus.contributor.auid 57217680794 -
scopus.contributor.auid 22935269100 -
scopus.contributor.auid 24821193900 -
scopus.contributor.auid 7003305969 -
scopus.contributor.auid 15832277800 -
scopus.contributor.auid 15925195000 -
scopus.contributor.auid 56685307000 -
scopus.contributor.auid 57202947460 -
scopus.contributor.auid 7201908392 -
scopus.contributor.auid 57193081662 -
scopus.contributor.auid 57204897107 -
scopus.contributor.auid 7004831221 -
scopus.contributor.auid 57201210118 -
scopus.contributor.auid 6508304628 -
scopus.contributor.auid 56973602500 -
scopus.contributor.auid 57195507652 -
scopus.contributor.auid 55851947319 -
scopus.contributor.auid 6701376562 -
scopus.contributor.auid 7004573619 -
scopus.contributor.auid 35557059700 -
scopus.contributor.auid 35589383200 -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Romania -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Brazil -
scopus.contributor.country Italy -
scopus.contributor.country Portugal -
scopus.contributor.country United States -
scopus.contributor.country Romania -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Italy -
scopus.contributor.country Austria -
scopus.contributor.country United States -
scopus.contributor.country Italy -
scopus.contributor.dptid 104540490 -
scopus.contributor.dptid 114083262 -
scopus.contributor.dptid 112878636 -
scopus.contributor.dptid 113922431 -
scopus.contributor.dptid 104760490 -
scopus.contributor.dptid 104157948 -
scopus.contributor.dptid 104540490 -
scopus.contributor.dptid 105268270 -
scopus.contributor.dptid 104254555 -
scopus.contributor.dptid 117498991 -
scopus.contributor.dptid 113010291 -
scopus.contributor.dptid 113010291 -
scopus.contributor.dptid 113010291 -
scopus.contributor.dptid 104760490 -
scopus.contributor.dptid 107734093 -
scopus.contributor.dptid 107734093 -
scopus.contributor.dptid 113092211 -
scopus.contributor.dptid 113870561 -
scopus.contributor.dptid 113870561 -
scopus.contributor.dptid 112139242 -
scopus.contributor.dptid 105268270 -
scopus.contributor.dptid -
scopus.contributor.dptid 103174985 -
scopus.contributor.dptid 103691512 -
scopus.contributor.dptid 104760490 -
scopus.contributor.dptid 104157948 -
scopus.contributor.dptid 113748268 -
scopus.contributor.dptid 112445098 -
scopus.contributor.dptid 113748268 -
scopus.contributor.dptid 112445098 -
scopus.contributor.dptid 103894504 -
scopus.contributor.dptid -
scopus.contributor.dptid 112445098 -
scopus.contributor.dptid 113092211 -
scopus.contributor.dptid 104540490 -
scopus.contributor.dptid 113767722 -
scopus.contributor.dptid -
scopus.contributor.dptid -
scopus.contributor.name M. -
scopus.contributor.name G. -
scopus.contributor.name M.D. -
scopus.contributor.name D. -
scopus.contributor.name F. -
scopus.contributor.name G. -
scopus.contributor.name G. -
scopus.contributor.name S. -
scopus.contributor.name R. -
scopus.contributor.name G. -
scopus.contributor.name G.M. -
scopus.contributor.name A. -
scopus.contributor.name F. -
scopus.contributor.name R. -
scopus.contributor.name F. -
scopus.contributor.name S. -
scopus.contributor.name P. -
scopus.contributor.name M. -
scopus.contributor.name R. -
scopus.contributor.name G.L. -
scopus.contributor.name P. -
scopus.contributor.name E. -
scopus.contributor.name R. -
scopus.contributor.name N. -
scopus.contributor.name A. R. Abu -
scopus.contributor.name M. -
scopus.contributor.name G.I. -
scopus.contributor.name Vincenzo -
scopus.contributor.name G. -
scopus.contributor.name P. -
scopus.contributor.name D. -
scopus.contributor.name A. -
scopus.contributor.name L. -
scopus.contributor.name V. -
scopus.contributor.name O. -
scopus.contributor.name S. -
scopus.contributor.name Guru -
scopus.contributor.name C. -
scopus.contributor.subaffiliation Division of Urology; -
scopus.contributor.subaffiliation Department of Medicine; -
scopus.contributor.subaffiliation Department of Cell and Molecular Biology; -
scopus.contributor.subaffiliation Department of Public Health; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Department of Emergency and Organ Transplantation;Urology;Andrology and Kidney Transplantation Unit; -
scopus.contributor.subaffiliation Division of Urology; -
scopus.contributor.subaffiliation Department of Experimental Medicine and Surgery; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Department of Biomedical Science; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Uro-Gynecological Department;Istituto Nazionale per lo Studio e la Cura dei Tumori; -
scopus.contributor.subaffiliation Uro-Gynecological Department;Istituto Nazionale per lo Studio e la Cura dei Tumori; -
scopus.contributor.subaffiliation Department of Neurosciences;Sciences of Reproduction and Odontostomatology;Urology Unit; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Departamento de Urologia; -
scopus.contributor.subaffiliation Division of Urology;Department of Experimental Medicine and Surgery;Urology Unit; -
scopus.contributor.subaffiliation Life and Health Sciences Research Institute; -
scopus.contributor.subaffiliation Division of Urology; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Department of Emergency and Organ Transplantation;Urology;Andrology and Kidney Transplantation Unit; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Department of Clinical Medicine and Surgery; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Department of Clinical Medicine and Surgery; -
scopus.contributor.subaffiliation Department of Translational Medical Sciences; -
scopus.contributor.subaffiliation Institute of Genetics and Biophysics “A. Buzzati-Traverso”; -
scopus.contributor.subaffiliation Department of Clinical Medicine and Surgery; -
scopus.contributor.subaffiliation Department of Neurosciences;Sciences of Reproduction and Odontostomatology;Urology Unit; -
scopus.contributor.subaffiliation Division of Urology; -
scopus.contributor.subaffiliation Department of Urology; -
scopus.contributor.subaffiliation Dana-Farber Cancer Institute;GU Oncology Division; -
scopus.contributor.subaffiliation -
scopus.contributor.surname Ferro -
scopus.contributor.surname Di Lorenzo -
scopus.contributor.surname Vartolomei -
scopus.contributor.surname Bruzzese -
scopus.contributor.surname Cantiello -
scopus.contributor.surname Lucarelli -
scopus.contributor.surname Musi -
scopus.contributor.surname Di Stasi -
scopus.contributor.surname Hurle -
scopus.contributor.surname Guazzoni -
scopus.contributor.surname Busetto -
scopus.contributor.surname Gabriele -
scopus.contributor.surname Del Giudice -
scopus.contributor.surname Damiano -
scopus.contributor.surname Perri -
scopus.contributor.surname Perdona -
scopus.contributor.surname Verze -
scopus.contributor.surname Borghesi -
scopus.contributor.surname Schiavina -
scopus.contributor.surname Almeida -
scopus.contributor.surname Bove -
scopus.contributor.surname Lima -
scopus.contributor.surname Autorino -
scopus.contributor.surname Crisan -
scopus.contributor.surname Farhan -
scopus.contributor.surname Battaglia -
scopus.contributor.surname Russo -
scopus.contributor.surname Ieluzzi -
scopus.contributor.surname Morgia -
scopus.contributor.surname De Placido -
scopus.contributor.surname Terracciano -
scopus.contributor.surname Cimmino -
scopus.contributor.surname Scafuri -
scopus.contributor.surname Mirone -
scopus.contributor.surname De Cobelli -
scopus.contributor.surname Shariat -
scopus.contributor.surname Sonpavde -
scopus.contributor.surname Buonerba -
scopus.date.issued 2020 *
scopus.description.abstracteng Background: Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG. Methods: We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model. Results: A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95% confidence interval 1.09–1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12–1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01–1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1–1.68); p = 0.005]. The limitations of a retrospective study are applicable. Conclusion: Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted. *
scopus.description.allpeopleoriginal Ferro M.; Di Lorenzo G.; Vartolomei M.D.; Bruzzese D.; Cantiello F.; Lucarelli G.; Musi G.; Di Stasi S.; Hurle R.; Guazzoni G.; Busetto G.M.; Gabriele A.; Del Giudice F.; Damiano R.; Perri F.; Perdona S.; Verze P.; Borghesi M.; Schiavina R.; Almeida G.L.; Bove P.; Lima E.; Autorino R.; Crisan N.; Farhan A.R.A.; Battaglia M.; Russo G.I.; Ieluzzi V.; Morgia G.; De Placido P.; Terracciano D.; Cimmino A.; Scafuri L.; Mirone V.; De Cobelli O.; Shariat S.; Sonpavde G.; Buonerba C. *
scopus.differences scopus.subject.keywords *
scopus.differences scopus.description.abstracteng *
scopus.document.type ar *
scopus.document.types ar *
scopus.identifier.doi 10.1007/s00345-019-02754-2 *
scopus.identifier.eissn 1433-8726 *
scopus.identifier.pmid 30993426 *
scopus.identifier.pui 627326069 *
scopus.identifier.scopus 2-s2.0-85064646644 *
scopus.journal.sourceid 20577 *
scopus.language.iso eng *
scopus.publisher.name Springer *
scopus.relation.firstpage 143 *
scopus.relation.issue 1 *
scopus.relation.lastpage 150 *
scopus.relation.volume 38 *
scopus.subject.keywords Basophils; BCG; Bladder cancer; *
scopus.title Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor *
scopus.titleeng Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor *
Appare nelle tipologie: 01.01 Articolo in rivista
File in questo prodotto:
File Dimensione Formato  
BCG.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 755.6 kB
Formato Adobe PDF
755.6 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/518413
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 56
social impact